.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,928,122

« Back to Dashboard

Claims for Patent: 7,928,122

Title:Modulators of cellular adhesion
Abstract: The present invention provides compounds having formula (I); ##STR00001## and pharmaceutically acceptable derivatives thereof, wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
Inventor(s): Shen; Wang (San Mateo, CA), Barr; Kenneth (San Francisco, CA), Oslob; Johan D. (Sunnyvale, CA), Zhong; Min (Foster City, CA)
Assignee: SARcode Corporation (Brisbane, CA)
Application Number:12/537,147
Patent Claims: 1. A compound of the following structure: ##STR00215## or pharmaceutically acceptable salts thereof; wherein --C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having the following structure: ##STR00216## R.sup.3A is hydrogen; R.sup.S is hydrogen; Ar.sub.2 is: ##STR00217## s is an integer of 1; each occurrence of R.sup.P1 is independently hydrogen, halogen, or -GR.sup.G1, wherein G is --SO.sub.2--, or --SO.sub.2NR.sup.G2--; and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; R.sup.E is hydrogen; R.sup.4A and R.sup.4B are each Cl; L is C.dbd.O; and AR.sub.1 is ##STR00218##

2. The compound of claim 1 wherein R.sup.P1 is selected from the group consisting of halogen and -GR.sup.G1, wherein G is --SO.sub.2-- and R.sup.G1 is methyl.

3. The compound of claim 2 wherein AR.sub.1 is ##STR00219## and R.sup.P1 is selected from the group consisting of F and SO.sub.2CH.sub.3.

4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent, and optionally further comprising an additional therapeutic agent.

5. A method of treating an immune or inflammatory response or disorder in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1, wherein the response or disorder is selected from psoriasis, inflammatory bowel disease, adult respiratory distress syndrome, dermatitis, meningitis, uveitis, eczema, asthma, poison ivy, poison oak, Sjogren's syndrome, pulmonary fibrosis, and rheumatoid arthritis.

6. The method of claim 5, further comprising concurrent, prior, or subsequent administration of an additional therapeutic agent.

7. A compound of the following structure: ##STR00220## or pharmaceutically acceptable salts thereof; wherein --C(.dbd.O)NHC(R.sup.1)(R.sup.2)R.sup.3 is a moiety having the following structure: ##STR00221## R.sup.3A is hydrogen; R.sup.S is hydrogen; Ar.sub.2 is: ##STR00222## s is an integer of 1; each occurrence of R.sup.P1 is independently hydrogen, halogen, or -GR.sup.G1, wherein G is --SO.sub.2--, or --SO.sub.2NR.sup.G2--; and R.sup.G1 and R.sup.G2 are independently hydrogen, an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; R.sup.B1, R.sup.B2 and R.sup.E are hydrogen; R.sup.4A and R.sup.4B are each Cl; L is C.dbd.O; and AR.sub.1 is ##STR00223##

8. The compound of claim 7 wherein R.sub.P1 is selected from the group consisting of halogen and -GR.sup.G1, wherein G is --SO.sub.2-- and R.sup.G1 is methyl.

9. The compound of claim 8 wherein AR.sub.1 is ##STR00224## and R.sup.P1 is selected from the group consisting of F and SO.sub.2CH.sub.3.

10. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier or diluent, and optionally further comprising an additional therapeutic agent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc